Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $15.60 Average Price Target from Analysts
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to […]
